AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2020-03-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 19271
- Registration Number
- NCT01991795
- Locations
- 🇻🇳
Research Site, Hochiminh, Vietnam
Study to Investigate Relative Bioavailability of up to Five Different Formulations of AZD5069
Phase 1
Completed
- Conditions
- Uncontrolled and Persistent Asthma
- Interventions
- Drug: Phase IIb formulationDrug: Putative phase III formulationDrug: Slow dissolution variant 1Drug: Slow dissolution variant 2Drug: Test treatment E
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT01989520
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Retrospective Swedish Cohort Study on Health Outcomes, Life Expectancy, Resource Use and Costs in Patients With a History of Myocardial Infarction and Additional Risk Factors for Atherothrombosis
Completed
- Conditions
- Acute Coronary Syndrome
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2014-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100000
- Registration Number
- NCT01984307
- Locations
- 🇸🇪
Research Site, Linkoping, Sweden
Retrospective Observational Study DIANA Study
Completed
- Conditions
- Major Depressive Episode
- First Posted Date
- 2013-11-06
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT01976793
- Locations
- 🇷🇺
Research Site, Yaroslavl, Russian Federation
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
Phase 3
Completed
- Conditions
- MetastaticUveal Melanoma
- Interventions
- First Posted Date
- 2013-11-03
- Last Posted Date
- 2017-01-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 152
- Registration Number
- NCT01974752
- Locations
- 🇬🇧
Research Site, Swansea, United Kingdom
To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
- First Posted Date
- 2013-11-01
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 39
- Registration Number
- NCT01974349
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.
Phase 2
Completed
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2013-10-30
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 158
- Registration Number
- NCT01972217
- Locations
- 🇬🇧
Research Site, Westcliff-on-Sea, United Kingdom
Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.
Phase 4
Completed
- Conditions
- COPDChronic Obstructive Pulmonary DiseaseModerate to Very Severe COPD
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-10-21
- Last Posted Date
- 2018-12-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3635
- Registration Number
- NCT01966107
- Locations
- 🇨🇦
Research Site, Quebec, Canada
BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects
Phase 1
Completed
- Conditions
- Gastric UlcerDuodenal UlcerAnastomotic UlcerReflux EsophagitisEtc.
- Interventions
- Drug: D961H sachet 20 mgDrug: D961H HPMC capsule 20 mg
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2013-12-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 34
- Registration Number
- NCT01964131
- Locations
- 🇯🇵
Research Site, Fukuoka-shi, Fukuoka, Japan
🇯🇵Hakata Clinic Medical Co. LTA, Fukuoka, Japan
Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD).
- Interventions
- First Posted Date
- 2013-10-16
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 84
- Registration Number
- NCT01962935
- Locations
- 🇬🇧
Research Site, London, United Kingdom